SG11202100145YA - Selective estrogen receptor degraders - Google Patents
Selective estrogen receptor degradersInfo
- Publication number
- SG11202100145YA SG11202100145YA SG11202100145YA SG11202100145YA SG11202100145YA SG 11202100145Y A SG11202100145Y A SG 11202100145YA SG 11202100145Y A SG11202100145Y A SG 11202100145YA SG 11202100145Y A SG11202100145Y A SG 11202100145YA SG 11202100145Y A SG11202100145Y A SG 11202100145YA
- Authority
- SG
- Singapore
- Prior art keywords
- estrogen receptor
- selective estrogen
- receptor degraders
- degraders
- selective
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Professional, Industrial, Or Sporting Protective Garments (AREA)
- Finger-Pressure Massage (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862697100P | 2018-07-12 | 2018-07-12 | |
US201962825172P | 2019-03-28 | 2019-03-28 | |
PCT/US2019/041342 WO2020014440A1 (en) | 2018-07-12 | 2019-07-11 | Selective estrogen receptor degraders |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202100145YA true SG11202100145YA (en) | 2021-02-25 |
Family
ID=67480324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202100145YA SG11202100145YA (en) | 2018-07-12 | 2019-07-11 | Selective estrogen receptor degraders |
Country Status (33)
Country | Link |
---|---|
US (1) | US20210260052A1 (en) |
EP (1) | EP3820874B1 (en) |
JP (1) | JP7085056B2 (en) |
KR (1) | KR102577142B1 (en) |
CN (1) | CN112424205B (en) |
AU (1) | AU2019299952B2 (en) |
BR (1) | BR112020025381A2 (en) |
CA (1) | CA3105491C (en) |
CL (1) | CL2021000046A1 (en) |
CO (1) | CO2021000041A2 (en) |
CR (1) | CR20210006A (en) |
DK (1) | DK3820874T3 (en) |
EC (1) | ECSP21001786A (en) |
ES (1) | ES2932867T3 (en) |
FI (1) | FI3820874T3 (en) |
HR (1) | HRP20230080T1 (en) |
HU (1) | HUE061032T2 (en) |
IL (1) | IL279990B2 (en) |
JO (1) | JOP20210004A1 (en) |
LT (1) | LT3820874T (en) |
MD (1) | MD3820874T2 (en) |
MX (1) | MX2021000377A (en) |
NZ (1) | NZ771719A (en) |
PE (1) | PE20211245A1 (en) |
PH (1) | PH12021550048A1 (en) |
PL (1) | PL3820874T3 (en) |
PT (1) | PT3820874T (en) |
RS (1) | RS63876B1 (en) |
SA (1) | SA521421006B1 (en) |
SG (1) | SG11202100145YA (en) |
SI (1) | SI3820874T1 (en) |
UA (1) | UA125890C2 (en) |
WO (1) | WO2020014440A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR122023020677A2 (en) | 2015-10-01 | 2023-12-12 | Olema Pharmaceuticals, Inc. | TETRAHYDRO-1H-PYRIDO[3,4-B]INDOL COMPOUNDS, COMPOSITIONS COMPRISING SAID COMPOUNDS AND USES THEREOF |
EA202190248A1 (en) | 2018-07-11 | 2021-06-16 | Х. Ли Моффитт Кэнсер Сентер Энд Рисерч Инститьют, Инк. | DIMERIC IMMUNOMODULATING COMPOUNDS AGAINST MECHANISMS BASED ON CEREBLON |
TWI702219B (en) * | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | Selective estrogen receptor degraders |
WO2023032873A1 (en) * | 2021-08-31 | 2023-03-09 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Method for producing monocyclic pyridine derivative |
US11926634B2 (en) | 2022-02-01 | 2024-03-12 | Eli Lilly And Company | Processes for the preparation of selective estrogen receptor degraders |
WO2024042157A1 (en) | 2022-08-25 | 2024-02-29 | Sanofi | Novel substituted quinoline and tetrahydronaphthalene carboxylic acid derivatives and therapeutic uses thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6756388B1 (en) * | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
US5521214A (en) * | 1995-01-25 | 1996-05-28 | Eli Lilly And Company | Methods of inhibiting environmental estrogens |
CA2218756A1 (en) * | 1996-10-25 | 1998-04-25 | Kristin Sue Marron | Substituted benzo¢b!thiophene compounds having activity as selective estrogen receptor modulators |
WO2002094788A1 (en) * | 2001-05-22 | 2002-11-28 | Eli Lilly And Company | 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods |
US7329654B2 (en) * | 2001-12-19 | 2008-02-12 | Janssen Pharmaceutica N.V. | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators |
CA2482986A1 (en) * | 2002-04-19 | 2003-10-30 | Signal Pharmaceuticals, Inc. | Benzopyranone compounds, compositions thereof, and methods of treatment therewith |
DE20301728U1 (en) * | 2002-10-11 | 2004-03-11 | Ligand Pharmaceuticals, Inc., San Diego | 5-substituted-7,9-difluoro-5H-chromeno (3,4-f) quinoline compounds as selective progesterone receptor modulator compounds |
CL2004000985A1 (en) * | 2003-05-16 | 2005-01-14 | Wyeth Corp | COMPOUNDS DERIVED FROM PHENYLQUINOLINS; PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS; AND USE TO TREAT OSTEOPOROSIS, PAGET DISEASE, VASCULAR DANO, OSTEOARTRITIS, OSEO CANCER, OVARIC CANCER, PROSTATIC CANCER, HYPERCHOLESTEROLEMIA, ATEROSC |
WO2005073204A1 (en) * | 2004-01-22 | 2005-08-11 | Eli Lilly And Company | Selective estrogen receptor modulators for the treatment of vasomotor symptoms |
US7354927B2 (en) * | 2004-09-07 | 2008-04-08 | Wyeth | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents |
US20080221163A1 (en) * | 2005-01-18 | 2008-09-11 | Jeffrey Alan Dodge | Selective Estrogen Receptor Modulators |
CA2915534A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Azetidine estrogen receptor modulators and uses thereof |
WO2016097071A1 (en) | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Estrogen receptor modulators and uses thereof |
CN107531722B (en) * | 2015-05-26 | 2020-07-17 | 豪夫迈·罗氏有限公司 | Heterocyclic estrogen receptor modulators and uses thereof |
CN109219604B (en) * | 2016-04-08 | 2021-09-24 | 豪夫迈·罗氏有限公司 | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
AU2018205262A1 (en) * | 2017-01-06 | 2019-07-11 | G1 Therapeutics, Inc. | Combination therapy for the treatment of cancer |
TWI702219B (en) * | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | Selective estrogen receptor degraders |
-
2019
- 2019-07-11 CN CN201980046170.4A patent/CN112424205B/en active Active
- 2019-07-11 CA CA3105491A patent/CA3105491C/en active Active
- 2019-07-11 SG SG11202100145YA patent/SG11202100145YA/en unknown
- 2019-07-11 NZ NZ771719A patent/NZ771719A/en unknown
- 2019-07-11 RS RS20230014A patent/RS63876B1/en unknown
- 2019-07-11 US US17/254,991 patent/US20210260052A1/en active Pending
- 2019-07-11 HR HRP20230080TT patent/HRP20230080T1/en unknown
- 2019-07-11 PT PT197462526T patent/PT3820874T/en unknown
- 2019-07-11 SI SI201930407T patent/SI3820874T1/en unknown
- 2019-07-11 MX MX2021000377A patent/MX2021000377A/en unknown
- 2019-07-11 BR BR112020025381-2A patent/BR112020025381A2/en unknown
- 2019-07-11 KR KR1020217000473A patent/KR102577142B1/en active IP Right Grant
- 2019-07-11 EP EP19746252.6A patent/EP3820874B1/en active Active
- 2019-07-11 FI FIEP19746252.6T patent/FI3820874T3/en active
- 2019-07-11 AU AU2019299952A patent/AU2019299952B2/en active Active
- 2019-07-11 PL PL19746252.6T patent/PL3820874T3/en unknown
- 2019-07-11 WO PCT/US2019/041342 patent/WO2020014440A1/en unknown
- 2019-07-11 PE PE2021000017A patent/PE20211245A1/en unknown
- 2019-07-11 JO JOP/2021/0004A patent/JOP20210004A1/en unknown
- 2019-07-11 DK DK19746252.6T patent/DK3820874T3/en active
- 2019-07-11 JP JP2021500586A patent/JP7085056B2/en active Active
- 2019-07-11 LT LTEPPCT/US2019/041342T patent/LT3820874T/en unknown
- 2019-07-11 MD MDE20210464T patent/MD3820874T2/en unknown
- 2019-07-11 HU HUE19746252A patent/HUE061032T2/en unknown
- 2019-07-11 ES ES19746252T patent/ES2932867T3/en active Active
- 2019-07-11 UA UAA202100103A patent/UA125890C2/en unknown
- 2019-07-11 CR CR20210006A patent/CR20210006A/en unknown
-
2021
- 2021-01-06 IL IL279990A patent/IL279990B2/en unknown
- 2021-01-06 CO CONC2021/0000041A patent/CO2021000041A2/en unknown
- 2021-01-07 CL CL2021000046A patent/CL2021000046A1/en unknown
- 2021-01-08 PH PH12021550048A patent/PH12021550048A1/en unknown
- 2021-01-11 EC ECSENADI20211786A patent/ECSP21001786A/en unknown
- 2021-01-12 SA SA521421006A patent/SA521421006B1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL295598A (en) | Selective estrogen receptor degraders | |
ZA201805573B (en) | Selective estrogen receptor degraders and uses thereof | |
IL285318A (en) | Estrogen receptor modulators | |
IL279990B1 (en) | Selective estrogen receptor degraders | |
ZA202003023B (en) | Benzothiophene-based selective estrogen receptor downregulators | |
IL268263B (en) | Estrogen receptor modulators | |
ZA202201157B (en) | Selective estrogen receptor degrader | |
EP3902545A4 (en) | Novel salts of selective estrogen receptor degraders | |
PL3500265T3 (en) | Estrogen receptor beta selective ligands |